Plavix Pharmacogenomic Label Update May Help Lilly With Effient Launch
Executive Summary
When Lilly's Effient (prasugrel) finally cleared FDA July 10, the first thing everyone noticed is the "black box" warning of a potential increased risk of bleeding associated with the antithrombotic drug
You may also be interested in...
The Biology Police: The Plavix Investigation and Pharmacogenomics
The discovery of a genetic marker for Plavix resistance is one of the milestones in the regulatory application of pharmacogenomics. Is it also a crime drama?
Effient Beats Plavix In Cost Study, But Will Results Pass Muster With Payers?
Lilly/Daiichi Sankyo's clot-buster Effient proved more cost-effective for acute coronary syndrome patients managed with percutaneous coronary intervention procedures than Bristol and Sanofi's soon-to-be generic Plavix in a large study funded by Lilly
Effient Beats Plavix In Cost Study, But Will Results Pass Muster With Payers?
Lilly/Daiichi Sankyo's clot-buster Effient proved more cost-effective for acute coronary syndrome patients managed with percutaneous coronary intervention procedures than Bristol and Sanofi's soon-to-be generic Plavix in a large study funded by Lilly